Nutritional labeling class actions have surged to historic levels in 2025-2026, driven primarily by the FDA’s “Healthy” label rule taking effect in April 2025 and state enforcement initiatives aligned with the Trump administration’s Make America Healthy Again (MAHA) Commission. The peak year of 2021 saw 325 class action cases filed against food and beverage companies, but litigation intensity has accelerated further as regulators and state attorneys general pursue enforcement where the federal government emphasizes voluntary industry compliance. A Consumer Reports investigation in October 2025 exemplified the problem: over two-thirds of protein products tested contained unsafe lead levels, sparking multiple lawsuits against manufacturers for mislabeling calories, fat content, and ingredient safety simultaneously. This surge reflects a fundamental shift in enforcement strategy.
Rather than centralized FDA rulemaking to force compliance, the MAHA approach relies on voluntary industry action and state-level initiatives. However, this gap has created opportunity for plaintiffs’ attorneys. Texas and Louisiana are leading a wave of mandatory labeling requirements and ingredient restrictions that are creating litigation flash points. Companies face simultaneous exposure from three angles: federal regulatory deadlines, state enforcement actions, and class action lawsuits from consumers who purchased products based on false or incomplete labels.
Table of Contents
- Why FDA Regulatory Changes Are Fueling Class Actions
- The MAHA Voluntary Approach and the State Enforcement Gap
- Protein Products and Heavy Metals—The Litigation Hot Spots
- Real Class Actions Filed in 2025-2026
- Functional Claims and Ingredient Dose-Insufficiency
- False Discount and Pricing Class Actions Expanding in 2026
- What to Expect in 2026 and Beyond
Why FDA Regulatory Changes Are Fueling Class Actions
The FDA’s “Healthy” label rule represents the most significant update to nutrient content claims in decades. The rule was effective as of April 28, 2025, on a voluntary basis, with full compliance required by January 1, 2028. This creates a compliance window where companies either voluntarily reformulate and relabel, or risk litigation exposure. The rule narrows what qualifies as “healthy”—stricter limits on sodium, added sugars, and saturated fat—which means products previously labeled as healthy no longer qualify under the new definition.
This regulatory framework directly correlates to the 2010-2020 trend where food labeling lawsuits nearly quintupled, from 45 cases in 2010 to 220 in 2020. The rule didn’t eliminate lawsuit risk; it redirected it. Companies that don’t update labels by the January 2028 deadline create explicit federal violations that plaintiffs’ attorneys use as use. However, even companies attempting to comply face litigation risk during the transition period, as the rule includes carve-outs and requires companies to choose between old and new standards, creating ambiguity that leads to disputes over what qualifies as “misleading” under California consumer protection laws.
The MAHA Voluntary Approach and the State Enforcement Gap
The Make America Healthy Again Commission published its report in September 2025 with a fundamentally different philosophy than traditional FDA regulation. Rather than enforceable federal rules, MAHA emphasizes voluntary industry action, industry partnerships, and removing what the commission views as burdensome regulations. This approach assumes companies will self-police once priorities are clear—reduce ultra-processed foods, remove harmful additives, improve ingredient transparency. The problem is enforcement authority.
When the federal government signals that compliance is voluntary, states move in to fill the gap. Texas and Louisiana have emerged as leaders in this enforcement void, enacting mandatory labeling requirements and ingredient restrictions that go beyond federal minimums. This creates a patchwork where companies must satisfy federal “healthy” standards, state-specific labeling requirements, and now simultaneously defend against class actions arguing that labels are misleading under state consumer protection statutes. For example, a product that technically complies with both federal and Texas labeling rules can still be sued in California for failing to disclose a “warning” that a state agency believes is material. This enforcement fragmentation is a primary driver of litigation surge.
Protein Products and Heavy Metals—The Litigation Hot Spots
Protein bars and powders have emerged as the single highest-risk category for nutritional labeling litigation. The category is large, the profit margins are significant, and consumer expectations about ingredient safety are high. David Protein Bars became a case study in 2025 when laboratory tests found that individual bars contained up to 83% more calories and up to 400% more fat than stated on the label. The lawsuit alleged that consumers were misled about the macronutrient composition of the product—a core nutritional claim that determines purchase decisions for fitness-conscious consumers.
Heavy metal contamination adds another dimension. Lead, cadmium, mercury, and arsenic are increasingly the focus of CPG (consumer packaged goods) lawsuits and state AG investigations. The Consumer Reports investigation from October 2025 found lead in more than two-thirds of protein products tested, with unsafe levels that would trigger California Prop 65 warnings in some cases. Baby food products are also under scrutiny—Texas AG investigations have focused specifically on heavy metal content in baby food products, creating liability for manufacturers who don’t proactively test and disclose. This is a litigation wedge: if a company knew or should have known about heavy metal presence (via industry knowledge of soil contamination, supply chain sourcing, or manufacturing processes), failure to disclose becomes a false labeling claim.
Real Class Actions Filed in 2025-2026
The New Chapter, Inc. class action filed in 2025 illustrates a growing litigation category: functional claims combined with dosing deception. New Chapter markets prebiotic and gut-health gummies and tablets. The lawsuit alleges that while the front label displays dosage information, consumers must purchase and consume multiple gummies or tablets to reach the advertised dose of active ingredients. The complaint argues this creates a false impression about product efficacy and value—the serving size on the back label reveals the deception, but the front-of-package marketing makes it appear that one gummy delivers the benefit advertised.
This case exemplifies the surge in litigation over “prebiotic,” “gut healthy,” and nootropic/adaptogen claims where plaintiffs argue dose-insufficiency makes the claims misleading. The Ole Mexican Foods lawsuit over Xtreme Wellness Tortilla Wraps provides a straightforward false labeling case: the nutritional label allegedly overstates dietary fiber content while understating carbohydrates and calories. This product is marketed to low-carb and keto diet consumers, for whom carbohydrate accuracy is a material purchasing factor. The lawsuit doesn’t allege contamination or safety issues—just basic nutritional inaccuracy. These cases are simpler to prove and defend than heavy metal or hidden ingredient claims, which is why they proliferate in court filings. The combination of David Protein Bars (macronutrient overstatement), New Chapter (dose deception), and Ole Mexican Foods (carb misstatement) shows the breadth of labeling vulnerabilities companies face across categories.
Functional Claims and Ingredient Dose-Insufficiency
The surge in functional claim litigation reflects consumer awareness about what “gut healthy,” “prebiotic,” and “nootropic” actually mean. However, companies frequently use these terms without either sufficient dose of the active ingredient or inclusion of ingredients that actively offset the benefit claim. For example, a product labeled as “gut healthy” because it contains probiotics might also contain artificial sweeteners that disrupt gut microbiota, or insufficient probiotic CFU count to provide clinical benefit. Plaintiffs’ attorneys are increasingly making the argument that such claims are inherently misleading when the dose is sub-therapeutic or when offsetting ingredients negate the claimed benefit.
A limitation of this litigation trend is that the science around many functional claims remains unsettled. Prebiotic dosing, optimal probiotic CFU counts, and even “healthy” itself lack uniform scientific consensus in many cases. This creates opportunity for defendants to argue that their labeling is reasonable based on available science, which can reduce settlement pressures. However, if a state attorney general or federal agency has taken a position on dosing or efficacy (as Texas AG has on baby food heavy metals), that position becomes a strong negotiating point for plaintiffs and significantly increases defense costs and settlement risk.
False Discount and Pricing Class Actions Expanding in 2026
Beyond nutritional accuracy, the 2026 litigation landscape is expanding to include pricing and discount representation. There’s an uptick in lawsuits challenging “Was/Now” comparisons and fictitious reference prices, where companies imply a higher regular price than actually charged to justify a discount. For example, a product priced at $9.99 with a “Was $19.99” label, where that $19.99 price was never or rarely offered, violates California’s unfair competition and false advertising statutes. While this isn’t purely nutritional labeling, it’s part of the broader food and beverage labeling class action surge.
These cases often run parallel to nutritional accuracy claims in the same lawsuit. A plaintiff alleges that a protein bar overstates calories while also claiming the discount price is misleading, creating multiple legal theories in one case. This bundling increases settlement values and defense costs, as defendants face exposure on multiple fronts. Companies that are aggressively discounting or using reference pricing in marketing should audit their promotional practices now, before these cases reach peak volume in mid-2026.
What to Expect in 2026 and Beyond
The full impact of the FDA “Healthy” label rule won’t be fully visible until the January 1, 2028 compliance deadline. Between now and then, expect litigation velocity to remain high or increase further, as companies in the transition period create labeling exposure and plaintiffs’ attorneys identify products that don’t yet comply with the new rule. State-level enforcement from Texas, Louisiana, and other MAHA-aligned states will likely intensify, particularly around heavy metal disclosure in baby food and ingredient transparency in protein products.
Class action attorneys are also beginning to coordinate across state lines, filing multi-state actions in federal court rather than individual state cases. This consolidation increases use and reduces the cost per defendant of fighting the claims, which actually increases settlement likelihood. Expect 2026 to see a plateau or slight decline in raw number of filings as cases consolidate, but an increase in average settlement values and aggregate exposure due to multi-state actions covering millions of consumers at once.